On May 15, 2025, Iovance Biotherapeutics, Inc. was sued for violations of the federal securities laws in the United States District Court for the Northern District of California on behalf of investors who purchased or otherwise
acquired Iovance securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.